Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||EML4 - ALK ALK F1174V ALK L1196M|
|Gene Variant Detail||
ALK F1174V (gain of function - predicted)
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EML4 - ALK ALK F1174V ALK L1196M||Advanced Solid Tumor||resistant||Lorlatinib||Preclinical - Cell culture||Actionable||In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).||29650534|